Cancer vaccine(Merck Sharp & Dohme Corp.)

Tech founder's dog was riddled withtumors, vets said she had months. He used ChatGPT to build a custom cancer vaccine that left researchers stunned Notes riddled with /ˈrɪdld wɪð/ 布满，充满（多指不好的东西） tumor /ˈtjuːmə(r)/n. 肿瘤 custom /ˈkʌstəm/adj. 定制的 vaccine /ˈvæksiːn/n. 疫苗 RUDRO CHAKRABARTI Mon, March 16, 2026, 5:05 AM When veterinarianstold Sydney tech entrepreneur Paul Conyngham that his rescue dog Rosie had months to live, he didn't accept the prognosis. Instead, the data scientist and machine learning engineer — with 17 years in the field but no background in biology — turned to ChatGPT and set out to do something no one had done before: build a personalized cancer vaccine for a dog. Notes veterinarian /ˌvetərɪˈneəriən/n.兽医 entrepreneur /ˌɒntrəprəˈnɜː(r)/n.企业家，创业者 rescue dog /ˈreskju dɒɡ/n. 救助犬，被救养的狗 prognosis /prɒɡˈnəʊsɪs/n. （病情）预后，预测 personalized /ˈpɜːsənəlaɪzd/adj.个性化的 Rosie had been diagnosed with advancedmast cell cancer in 2024. Chemotherapy slowed the spread but couldn't shrink her tumors. So Conyngham spent $3,000 to have Rosie's healthy DNA and tumor DNA sequenced at the University of New South Wales, then used AI tools — including AlphaFold, a protein-modeling system — to pinpoint the mutations driving her cancer and identify potential drug targets. Notes advanced /ədˈvɑːnst/adj. 晚期的，严重的 mast cell cancer /mɑːst sel ˈkænsə(r)/ 肥大细胞瘤 chemotherapy /ˌkiːməʊˈθerəpi/n.化疗 sequence /ˈsiːkwəns/v. 测序 AlphaFold（阿尔法折叠）是谷歌旗下 DeepMind 开发的、基于深度学习的蛋白质结构预测 AI，革命性地解决了生物学 50 年难题，能从氨基酸序列高精度预测蛋白质 3D 结构，精度接近冷冻电镜等实验黄金标准。 protein-modeling /ˈprəʊtiːn ˈmɒdlɪŋ/n.蛋白质建模 pinpoint /ˈpɪnpɔɪnt/v. 精准定位，查明 mutation /mjuːˈteɪʃn/n. 突变 drug target /drʌɡ ˈtɑːɡɪt/n. 药物靶点 "We took her tumor, sequenced the DNA, we converted it from tissue to data, and we used that to find the problem in her DNA and then develop a cure based off that," Conyngham told Australia's Today Show. "ChatGPT assisted throughout the entire process." Notes convert /kənˈvɜːt/v. 转换 tissue /ˈtɪʃuː/n. 组织 When a pharmaceutical company refused to supply a promising immunotherapy drug for compassionate use, Conyngham pivoted. He worked with UNSW's RNA Institute to manufacture a custom mRNA vaccine from his AI-generated formula. Notes pharmaceutical /ˌfɑːməˈsjuːtɪkl/adj. 制药的 immunotherapy /ˌɪmjənəʊˈθerəpi/n.免疫疗法 compassionate use /kəmˈpæʃənət juːz/ 同情用药（重病患者紧急使用未上市药） pivot /ˈpɪvət/v. 转变方向，转向 UNSW RNA Institute（新南威尔士大学 RNA 研究所）是澳大利亚顶尖、国家级的 RNA 科学与转化研究中心，由UNSW Sydney于2021 年成立，核心定位是整合 RNA 生物学、化学、医学，打造从基础研究到药物 / 疫苗生产的完整 RNA 生态系统，也是南半球最重要的 RNA 研究枢纽之一。 mRNA /ˌem ɑːr ˈneɪ/ 信使 RNA，就是细胞里的“信使”，负责把细胞核里 DNA 的遗传信息，带到细胞质里，指导合成蛋白质。 formula /ˈfɔːmjələ/n. 配方，方案 Less than two months after the sequence was finalized, Rosie received her first injection last December — and by mid-March, the tennis ball-sized tumor on her leg had shrunk by roughly 75%, according to Conyngham's March 15 appearance on Australia's Today Show. Notes finalize /ˈfaɪnəlaɪz/v. 敲定，最终确定 injection /ɪnˈdʒekʃn/n. 注射，针剂 "At the start of December her mobility was way down, she started to shut down and be a bit sad," Conyngham told The Australian. "And towards the end of January, she was jumping over a fence to chase a rabbit." Notes mobility /məʊˈbɪləti/n. 活动能力，移动性 shut down /ʃʌt daʊn/ （身体 / 精神）衰退，垮掉 Researchers at UNSW say it's the first personalized cancer vaccine ever designed for a dog. "It raises the question, if we can do this for a dog, why aren't we rolling this out to all humans with cancer?" said Martin Smith, director of the UNSW Ramaciotti Centre for Genomics. Note roll out /rəʊl aʊt/v. 推出，推广应用 Páll Thordarson, director of the UNSW RNA Institute, called the achievement a sign of things to come. "This is the first time a personalized cancer vaccine has been designed for a dog ... ultimately, we're going to use this for helping humans," he told The Australian, adding that Conyngham's ability to generate an mRNA recipe with no biology training shows the technology is "democratizing the whole process." Note democratize /dɪˈmɒkrətaɪz/v. 使普及，使大众化 The bigger picture for human medicine Rosie's story is remarkable on its own. But for investors, the real signal is what it validates: the same mRNA platform technology is already being tested in dozens of human clinical trials by some of the biggest names in pharma— and the most advanced programs are nearing potential regulatory approval. Notes validate /ˈvælɪdeɪt/v. 证实，验证 clinical trial /ˈklɪnɪkl ˈtraɪəl/n.临床试验 pharma /ˈfɑːmə/n. 制药行业（pharmaceutical 简写） near /nɪə(r)/v. 接近 regulatory approval /ˈreɡjələtəri əˈpruːvl/n. 监管批准，上市许可 Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) are leading the pack. Their jointly developed personalized melanoma vaccine — now called intismeran autogene — showed a 49% reduction in the risk of cancer recurrence or death over five years of follow-up when combined with Merck's blockbuster immunotherapy drug Keytruda, according to data Merck released in January 2026 . The five-year hazard ratio held steady at 0.51, identical to the three-year mark — suggesting the vaccine trains the immune system to keep surveilling for cancer cells well beyond the treatment window. Notes Moderna (莫德纳) — mRNA 技术开创者，股票代码：NASDAQ: MRNA Merck (默克 / 默沙东) —全球制药巨头 股票代码：NYSE: MRK（美国 / 加拿大称 Merck，全球称 MSD） melanoma /ˌmeləˈnəʊmə/n. 黑色素瘤 Intismeran Autogene（通用名：intismeran autogene；研发代号：mRNA-4157 / V940）是由 Moderna (MRNA) 与 Merck (MRK) 联合开发的全球首个进入 III 期临床的个体化 mRNA 癌症疫苗，也是目前疗效最明确、进展最快的 mRNA 肿瘤药。 recurrence /rɪˈkʌrəns/n. 复发 follow-up /ˈfɒləʊ ʌp/n. 随访，跟踪观察 blockbuster /ˈblɒkbʌstə(r)/adj.畅销的，王牌的 Keytruda帕博利珠单抗药= 免疫系统的“刹车松绑器” 癌细胞通过 PD-L1 绑定免疫 T 细胞的 PD-1，给免疫踩“刹车”。 Keytruda 堵住 PD-1，松开刹车，让 T 细胞恢复战斗力，追杀癌细胞。 hazard ratio /ˈhæzəd ˈreɪʃiəʊ/n.风险比 identical /aɪˈdentɪkl/adj. 相同的 surveil /sɜːˈveɪl/v. 监视，监测 treatment window /ˈtriːtmənt ˈwɪndəʊ/治疗窗口期 Phase 3 trials are now underway for melanoma and non-small-cell lung cancer, with interim results from the melanoma trial potentially available later this year. Additional Phase 2 studies are running in kidney cancer and bladder cancer. Jefferies analysts have estimated the vaccine could be priced similarly to Keytruda — around $200,000 per patient — and could achieve multibillion-dollar peak sales in melanoma alone. Notes non-small-cell lung cancer非小细胞肺癌 interim /ˈɪntərɪm/adj. 中期的，临时的 kidney /ˈkɪdni/n. 肾脏 bladder /ˈblædə(r)/n. 膀胱 peak sales /piːk seɪlz/n. 销售峰值 BioNTech (NASDAQ: BNTX), the German company behind the Pfizer COVID vaccine, is running its own mRNA cancer vaccine program in partnership with Genentech. Their personalized vaccine — autogene cevumeran — showed immune responses persisting for up to nearly four years in a Phase 1 pancreatic cancer trial at Memorial Sloan Kettering, with patients who responded to the vaccine showing delayed tumor recurrence compared to those who didn't. Notes BioNTech (NASDAQ: BNTX)，全称 Biopharmaceutical New Technologies，是德国（美因茨）的全球顶尖 mRNA 生物技术公司，与 Moderna (MRNA) 并称全球 mRNA 双雄。它因与辉瑞 (Pfizer) 合作开发新冠疫苗 Comirnaty 而一战成名，目前正全力转型为全球癌症免疫治疗巨头。 persist /pəˈsɪst/v. 持续，留存 pancreatic cancer /ˌpæŋkriˈætɪk ˈkænsə(r)/ 胰腺癌 Memorial Sloan Kettering Cancer Center (MSK / MSKCC) —纪念斯隆 - 凯特琳癌症中心，是全球癌症治疗与科研的绝对巅峰，也是 Moderna、BioNTech、Keytruda 等所有巨头最核心的临床试验基地与学术支柱。 A larger Phase 2 trial is now enrolling at sites worldwide. BioNTech is also testing mRNA vaccines for colorectal cancer and melanoma, though its oncology timeline trails Moderna's. Notes enroll /ɪnˈrəʊl/v. 招募（受试者） colorectal cancer /ˌkɒləˈrektl ˈkænsə(r)/ 结直肠癌 oncology /ɒŋˈkɒlədʒi/n. 肿瘤学 timeline /ˈtaɪmlaɪn/n. 时间线，研发进度 trail /treɪl/v. 落后，滞后 All told, more than 400 clinical trials testing cancer vaccines of all types have been initiated globally over the last three years, according to data from the National Library of Medicine — roughly 120 of which are testing mRNA-based approaches specifically. The broader mRNA therapeutics market was valued at roughly $7.7 billion in 2025 and is expected to grow significantly as oncology programs advance, according to BCC Research. Notes all told /ɔːl təʊld/ 总而言之，合计 National Library of Medicine美国国家医学图书馆 therapeutics /ˌθerəˈpjuːtɪks/n.治疗学，疗法 What investors should know Moderna and Merck offer the most direct way into this space. Moderna's entire growth narrative is pivoting from its pandemic-era COVID vaccine business toward oncology — its personalized cancer vaccine is the company's flagship pipeline asset. Merck brings Keytruda, already one of the best-selling drugs in the world, as the combination partner. Notes flagship /ˈflæɡʃɪp/adj. 旗舰的，核心的 pipeline /ˈpaɪplaɪn/n. 研发管线（在研产品） combination partner（生物医药语境）联合伙伴 / 联用搭档 与另一款药物联合使用（combination therapy）、产生协同增效的药物（或公司）。 But the investment case comes with real risk. Moderna reported full-year 2025 revenue of $1.9 billion, a 40% decline from $3.2 billion the prior year, driven by falling COVID vaccine demand. Notes investment case /ɪnˈvestmənt keɪs/投资逻辑 revenue /ˈrevənjuː/n. 收入，营收 The company continues to operate at a loss — its full-year net loss narrowed to $2.8 billion from $3.6 billion in 2024, but it's still burning through cash as it funds a sprawling pipeline. Moderna ended 2025 with $8.1 billion in cash and investments, and management is targeting breakeven by 2028. Notes operate at a loss /ˈɒpəreɪt æt ə lɒs/ 亏损运营 net loss /net lɒs/n. 净亏损 narrow /ˈnærəʊ/v. 收窄，减少 burn through cash /bɜːn θruː kæʃ/烧钱，快速消耗现金 sprawling /ˈsprɔːlɪŋ/adj. 庞大的，广泛的 breakeven /ˈbreɪk iːvn/n. 盈亏平衡 Adding to the uncertainty: the FDA initially issued a Refusal-to-File for Moderna's U.S. flu vaccine submission in February 2026 — a decision STAT News reported was made by FDA CBER head Vinay Prasad over the objections of career staff — though the agency subsequently reversed course and accepted an amended application later that month, with a decision expected by August. Notes refusal-to-file /rɪˈfjuːzl tu faɪl/n. 不予受理 STAT News (STAT) = 全球生物医药、医疗、生命科学领域最权威、最具影响力的行业媒体。 FDA CBER = 美国 FDA 生物制品评估与研究中心（Center for Biologics Evaluation and Research） submission /səbˈmɪʃn/n. 提交（申请） objection /əbˈdʒekʃn/n. 反对 subsequently /ˈsʌbsɪkwəntli/adv.随后，后来 reverse course /rɪˈvɜːs kɔːs/ 改变方向，撤销决定 amend /əˈmend/v. 修改，修订 application /ˌæplɪˈkeɪʃn/n. 申请 Federal health officials have also scaled back hundreds of millions in mRNA research grants under the Trump administration, including the termination of roughly $500 million in mRNA vaccine contracts through the Biomedical Advanced Research and Development Authority (BARDA). Notes scale back /skeɪl bæk/v. 缩减，削减 grant /ɡrɑːnt/n. 拨款，资助 administration /ədˌmɪnɪˈstreɪʃn/n.政府，执政当局 termination /ˌtɜːmɪˈneɪʃn/n. 终止，结束 Biomedical Advanced Research and Development Authority 美国生物医学高级研究与发展管理局 BioNTech is another name to watch, though its oncology programs are at an earlier stage, with its lead cancer vaccine candidates still in Phase 1 and 2 trials. Note candidate /ˈkændɪdət/n. 候选药物 The approach itself also has real practical hurdles that go beyond any single company. Each vaccine must be custom-manufactured for an individual patient based on their tumor's unique mutations — a process that currently takes roughly 30 days to produce, according to Moderna CEO Stéphane Bancel, and costs upward of $100,000 per patient by industry estimates. Scaling that across millions of cancer patients is a manufacturing and logistics problem no one has cracked yet. Notes hurdle /ˈhɜːdl/n. 障碍，困难 scale /skeɪl/v. 规模化 logistics /ləˈdʒɪstɪks/n. 物流 crack /kræk/v. 解决，破解 "Cancer is heterogeneous, meaning patients with the same type of breast cancer might have tumors with different molecular signatures," Mansoor Amiji, a pharmaceutical sciences professor at Northeastern University whose team recently published a review of the field, told Northeastern Global News. "We need to almost go towards a personalized therapy model, but personalized therapy is hard to do." Notes heterogeneous /ˌhetərəˈdʒiːniəs/adj.异质性的，各不相同的 molecular /məˈlekjələ(r)/adj. 分子的 signature /ˈsɪɡnətʃə(r)/n. 特征，信号 The takeaway What a tech entrepreneur with a sick dog and a ChatGPT subscription demonstrated in a matter of months — going from tumor biopsy to custom mRNA treatment using AI — is the same process that Moderna, Merck and BioNTech are spending billions to industrialize for human patients. Notes takeaway /ˈteɪkəweɪ/n. 要点，结论 subscription /səbˈskrɪpʃn/n. 订阅 demonstrate /ˈdemənstreɪt/v. 证明，展示 biopsy /ˈbaɪɒpsi/n. 活检 industrialize /ɪnˈdʌstriəlaɪz/v.产业化，工业化 It's not a cure. Conyngham is the first to say so: one of Rosie's tumors didn't respond, and the team is already sequencing it to design a second vaccine. But AI-driven drug design, falling sequencing costs and proven mRNA delivery platforms are pushing personalized cancer vaccines out of the lab and into late-stage trials with real data behind them. For investors, the question isn't whether this technology works. The five-year melanoma data suggests it does. The question is which companies can manufacture it at scale, get it through a shifting regulatory environment and turn a one-patient-at-a-time treatment into a commercially viable product. That race is well underway. Note shifting /ˈʃɪftɪŋ/adj. 不断变化的 And for Rosie? She's still here — jumping fences, chasing rabbits and living proof that a guy with a laptop, a sick dog and a stubborn refusal to accept the odds can push science forward in ways nobody saw coming. Notes living proof /ˈlɪvɪŋ pruːf/n. 活生生的证明 odds /ɒdz/n. 几率，逆境，胜算English Summary Sydney tech entrepreneur and data scientist Paul Conyngham (17 years in ML, no biology background) refused to accept vets’ prognosis that his rescue dog Rosie had only months to live with advanced mast cell cancer (chemo failed to shrink tumors). He spent $3,000 to sequence Rosie’s healthy/tumor DNA at UNSW, then used ChatGPT + AlphaFold to identify cancer-driving mutations and design a custom mRNA cancer vaccine. After a drug company denied compassionate use of immunotherapy, he partnered with UNSW’s RNA Institute to manufacture the vaccine. Rosie received her first shot in Dec 2025; by mid-March 2026, her leg tumor shrank ~75%, and her mobility/quality of life fully recovered. This marks the first personalized cancer vaccine for a dog. The story validates the mRNA cancer platformalready in late-stage human trials (Moderna/Merck, BioNTech). While promising, hurdles remain: high cost (~$100k+ per patient), 30-day manufacturing time, and scaling challenges. For investors, the key is which firm can industrialize this AI-driven personalized treatment at scale. 中文梗概 悉尼科技创业者、数据科学家保罗・康宁汉姆（拥有 17 年机器学习经验，无生物学背景），在兽医判定其救助犬罗茜罹患晚期肥大细胞瘤、仅剩数月生命（化疗仅延缓扩散、无法缩小肿瘤）后，拒绝接受命运。他自费 3000 美元在新南威尔士大学（UNSW）完成罗茜健康与肿瘤 DNA 测序，并用ChatGPT + AlphaFold定位致癌突变、设计定制化 mRNA 癌症疫苗。因药企拒绝同情用药，他转而与 UNSW RNA 研究所合作生产疫苗。 罗茜于 2025 年12 月首次接种；至 2026 年 3 月中旬，腿部网球大肿瘤缩小约 75%，活动能力与生活质量完全恢复。这是全球首例犬类个性化癌症疫苗。 该事件验证了mRNA 癌症技术平台的可行性（Moderna / 默克、BioNTech 已进入人体后期临床试验）。但仍存瓶颈：单例成本超 10 万美元、生产需 30 天、规模化难题待解。对投资者而言，核心是哪家企业能将 AI 驱动的个性化疗法实现工业化量产。